370 related articles for article (PubMed ID: 33661508)
1. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.
Mrowietz U; Burden AD; Pinter A; Reich K; Schäkel K; Baum P; Datsenko Y; Deng H; Padula SJ; Thoma C; Bissonnette R
Dermatol Ther (Heidelb); 2021 Apr; 11(2):571-585. PubMed ID: 33661508
[TBL] [Abstract][Full Text] [Related]
2. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
[TBL] [Abstract][Full Text] [Related]
3. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
[TBL] [Abstract][Full Text] [Related]
4. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.
Choon SE; Lebwohl MG; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Rajeswari S; Deng H; Tetzlaff K; Thoma C; Bachelez H
BMJ Open; 2021 Mar; 11(3):e043666. PubMed ID: 33785490
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
Morita A; Tsai TF; Yee EYW; Okubo Y; Imafuku S; Zheng M; Li L; Quaresma M; Thoma C; Choon SE
J Dermatol; 2023 Feb; 50(2):183-194. PubMed ID: 36282833
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
[TBL] [Abstract][Full Text] [Related]
7. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
Morita A; Choon SE; Bachelez H; Anadkat MJ; Marrakchi S; Zheng M; Tsai TF; Turki H; Hua H; Rajeswari S; Thoma C; Burden AD
Dermatol Ther (Heidelb); 2023 Jan; 13(1):347-359. PubMed ID: 36333618
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.
Okubo Y; Kobayashi S; Murakami M; Sano S; Kikuta N; Ouchi Y; Terui T
Am J Clin Dermatol; 2024 Jul; ():. PubMed ID: 38954226
[TBL] [Abstract][Full Text] [Related]
9. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study.
Bissonnette R; Abramovits W; Saint-Cyr Proulx É; Lee P; Guttman-Yassky E; Zovko E; Sigmund R; Willcox J; Bieber T
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):549-557. PubMed ID: 36376738
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T; Okubo Y; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Uehara N; Handa T; Tanaka M; Zhang W; Paris M; Murakami M
Am J Clin Dermatol; 2023 Sep; 24(5):837-847. PubMed ID: 37233897
[TBL] [Abstract][Full Text] [Related]
11. Trial of Spesolimab for Generalized Pustular Psoriasis.
Bachelez H; Choon SE; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Anadkat MJ; Rajeswari S; Hua H; Vulcu SD; Hall D; Tetzlaff K; Thoma C; Lebwohl MG;
N Engl J Med; 2021 Dec; 385(26):2431-2440. PubMed ID: 34936739
[TBL] [Abstract][Full Text] [Related]
12. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
Elewski BE; Lebwohl MG; Anadkat MJ; Barker J; Ghoreschi K; Imafuku S; Mrowietz U; Li L; Quaresma M; Thoma C; Bachelez H
J Am Acad Dermatol; 2023 Jul; 89(1):36-44. PubMed ID: 36870370
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial.
Tsai TF; Zheng M; Ding Y; Song Z; Liu Q; Chen Y; Hu H; Xu J
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3097-3110. PubMed ID: 37840119
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
[TBL] [Abstract][Full Text] [Related]
15. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial.
Alavi A; Prens E; Kimball AB; Frew JW; Krueger JG; Mukhopadhyay S; Gao H; Ranganathan U; Ivanoff NB; Hernandez Daly AC; Zouboulis CC
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38576350
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.
Burden AD; Okubo Y; Zheng M; Thaçi D; van de Kerkhof P; Hu N; Quaresma M; Thoma C; Choon SE
Exp Dermatol; 2023 Aug; 32(8):1279-1283. PubMed ID: 37140190
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis.
Bissonnette R; Maari C; Tsianakas A; Reid D; McCutchan S; Baumgartner S; Mackay J; Bhakta N
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2179-2193. PubMed ID: 34716902
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations.
Freitas E; Rodrigues MA; Torres T
Clin Cosmet Investig Dermatol; 2020; 13():561-578. PubMed ID: 32884319
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
